In the placebo-controlled SORMAIN trial, Burchert and coworkers were able to show that maintenance therapy with sorafenib significantly improves outcome after alloHCT in FLT3-ITD-mutated AML with a 2-year relapse-free survival (RFS) of 85% in the sorafenib group vs 53.3% in the placebo group (p= .002) (21). Here, FLT3 is linked to acute myeloid leukemia.